Last Update: Jul 01, 2026 Specified Use-Results Study of ILARIS Solution for S.C. Injection (Schnitzler's Syndrome) ClinicalTrials.gov Identifier: [NCT07598422](https://clinicaltrials.gov/ct2/show/NCT07598422) Novartis Reference Number:CACZ885C21401 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The aim of this study is to assess the effectiveness and safety of Ilaris (canakinumab) in clinical use in patients with Schnitzler's syndrome. Condition Schnitzler Syndrome Overall Status Recruiting Number of Participants10 Start Date May 13, 2026 Completion Date Jun 30, 2032 Gender All Age(s) 0 Years - (Child, Adult, Older Adult) ## Eligibility Criteria Inclusion criteria 1\\. Patients diagnosed with Schnitzler's syndrome using canakinumab for the first time for the indication of Schnitzler's syndrome as described in the package insert. Patients starting treatment with canakinumab before conclusion of the contract for this study will also be included in the study so that all patients diagnosed with Schnitzler's syndrome who received canakinumab will be registered in this study. Exclusion criteria 1\. Patients previously treated with canakinumab in Study IACT21071. 2\. All patients treated with canakinumab for the following indications: Indications: Cryopyrin-associated periodic syndromes (familial cold autoinflammatory syndrome, Muckle-Wells syndrome, neonatal onset multisystem inflammatory disease), hyper immunoglobulin D (IgD) syndrome (mevalonate kinase deficiency), tumor necrosis factor (TNF) receptor-associated periodic syndrome, familial mediterranean fever, systemic juvenile idiopathic arthritis, adult-onset Still's disease. 3\. Patients receiving canakinumab for off-label use under the Clinical Trials Act or GCP (e.g., patient-proposed healthcare services, investigator-initiated clinical trial). Japan #### Novartis Investigative Site Recruiting Kanoya,Kagoshima-ken,893-0024,Japan #### Novartis Investigative Site Recruiting Osaka,5458586,Japan ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: